Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eculizumab biosimilar - Generium

Drug Profile

Eculizumab biosimilar - Generium

Alternative Names: Elizaria

Latest Information Update: 11 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GENERIUM Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 07 Dec 2019 Efficacy, safety, pharmacokinetics and immunogenicity data from a phase III trial in Paroxysmal nocturnal haemoglobinuria presented at 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2019)
  • 07 Dec 2019 GENERIUM completes a phase III trial in Paroxysmal nocturnal haemoglobinuria in Russia (Parenteral) before December 2019
  • 06 Dec 2019 GENERIUM initiates a phase III trial in Paroxysmal nocturnal haemoglobinuria in Russia (Parenteral) before December 2019
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top